MiMedx Group, Inc. expected to post a loss of 1 cent a share - Earnings Preview

What happened

MiMedx Group is expected to report a 39.7% revenue decrease to $68.553 million for the quarter ending September 30, 2026, according to five analysts' average estimate. The company is expected to post a loss of 1 cent a share when it reports on October 28.

Confirmed

Global impact / market context

A 39.7% revenue drop would shrink the cash MiMedx generates from sales, making it harder to cover fixed costs and protect profit per sale. The expected 1-cent loss signals analysts see earnings pressure, which can weigh on the share price.

Analyst inference

Analysts rate MiMedx "buy" with a median 12-month price target of $8.00, about 107.8% above its last close of $3.85. That gap suggests investors expect recovery, yet revenue estimates were unchanged in three months.

Analyst inference

What to watch

1. Watch whether reported revenue lands near the $68.553 million average estimate and whether the loss matches the expected 1 cent a share when results are released October 28. Confirmed
2. Watch actual gross profit margin against company guidance of 74% to 76% for the quarter ended September 30, 2026, since a shortfall would reduce profit per sale. Confirmed
3. Watch whether MiMedx misses earnings estimates again, as it did in the two prior quarters, which could challenge the buy ratings and the $8.00 median price target. Analyst inference

Evidence

• Original source link unavailable